100% premium: Novartis buys antibiotics specialists Neutec Pharma


London – Another UK biotech company was taken over when Novartis signed a recommended all-cash offer worth Euro435 million for the antibiotics specialists Neutec pharma. The Swiss pharma giant paid more than twice of the Manchester-based company’s market capitalization before the takeover approach. Buying Neutec gives Novartis access to two advanced stage antibody products for serious hospital-acquired infections: Mycograb, for treating systemic fungal infections and Aurograb, for treating methicillin-resistant Staphylococcus aureus. Daniel Vasella, CEO of Novartis, said the products “promise to dramatically improve treatments in the area and will also enable Novartis to strengthen its biologics pipeline and anti-infective drug portfolio.” Mycograb has been filed in Europe and has been approved for compassionate use, while Aurograb is in phase III. NeuTec has retained 100% ownership of its products. The buyout is a big payday for the founders Ruth Mathews and James Burnie, who still own a 7% stake. During the takeover negotiations the founders secured NeuTecs operations at the current facility in Manchester for at least two years. The sale of the company came just three weeks after AstraZeneca agreed to buy Cambridge Antibody for Euro1.1 billion. Besides the Neutec deal the antibiotics market has seen amany known players disappear. One of the most prominent was the US-based Vicuron, bought by Pfizer for $1.9 billion. New companies have nevertheless emerged as Roche (Basilea), Sanofi-Aventis (Novexel), Sandoz (Nabriva) and Bayer (Aicuris) span out their infectious disease businesses.

Tech Review


Molecular diagnostics (MDx), a branch of in vitro diagnostics, is based on the determination of nucleic acid sequences, mainly for medical applications. This sequence determination is largely performed using methods based on...



British gene therapy specialist Oxford BioMedica plc (Oxford, UK) announced that its Chairman Dr. Alan Kingsman will leave the Board on 5 May, 2011 but will remain a consultant to the company. Nick Rodgers, the company’s...

Clinical Trial


Swiss Novartis AG’s (Basel) hepatitis C (HCV) first-in-class antiviral alisporivir (DEB025) has met the primary endpoint in a Phase IIb study. 76% of chronic hepatitis C patients with the most common G1 geno­type treated with...

Clinical Trial


Austrian Affiris AG’s (Vienna) short peptide AD02, which mimics the N-terminal portion of the Ab 40-42-peptide, has met its safety endpoints and shown the first signs of efficacy in a Phase I trial with 12 Alzheimer patients and...



Alexander von Gabain, CEO and co-founder of Austrian vaccine specialist Intercell AG, has been elected to chair the prestigious European Institute of Innovation and Technology (EIT) in Budapest. The geneticist will succeed Martin...

Clinical Trial


Munich – Curacyte AG has reported positive interim results in its ongoing Phase III study with PHP as a treatment for patients suffering from catecholamine-resistant distributive shock. The independent data monitoring board has...

Politics / Law


Brussels/Strasbourg – A conflict over a marketing ban of foods produced from the offspring of cloned animals has disrupted the plans of the European Commission and the EU Council to modernise the EU’ s Novel Food Regulation from...



Brussels – Up to now the European Research Council (ERC) exclusively funded excellent fundamental research encouraging researchers to think outside the box. With the new EU Innovation Union, the Organisation, which has a budget...

Clinical Trial


Zurich – Nycomed Pharma AG has submitted an MAA to the European Medicines Agency for its recombinant human glucagon-like peptide mimic teduglutide (Revestive®) as a once-daily treatment for Short Bowel Syndrome, a condition in...

Displaying results 171 to 180 out of 1983

< Previous 171-180 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%


  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%


  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%


  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%


  • KARO BIO (S)33.00 SEK1962.5%
  • NICOX (F)9.62 EUR425.7%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%


  • BB BIOTECH (D)44.83 EUR-84.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 29.07.2016


All Events